Home Tools
Log in


Catalog No. T2119   CAS 1257044-40-8
Synonyms: GDC-0199, ABT 199, ABT-199, ABT199

Venetoclax (ABT-199) is a Bcl-2 inhibitor (Ki<0.01 nM) with potent, selective, and orally active properties. Venetoclax has a 3-order-of-magnitude lower affinity for Bcl-xL and Bcl-W (Kis=48/245 nM). Venetoclax induces autophagy and apoptosis.

All TargetMol products are for research or drug registration purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose in violation of laws and regulations.
Venetoclax Chemical Structure
Venetoclax, CAS 1257044-40-8
Pack Size Availability Price/USD Quantity
5 mg In stock
$ 48.00
$ 38.40
10 mg In stock
$ 68.00
$ 54.40
50 mg In stock
$ 89.00
$ 71.20
100 mg In stock
$ 116.00
$ 92.80
500 mg In stock
$ 382.00
$ 305.60
1 g In stock
$ 596.00
$ 476.80
1 mL * 10 mM (in DMSO) In stock
$ 66.00
$ 52.80
Bulk Inquiry
Get quote
Select Batch  
Purity: 99.96%
Purity: 99.92%
Purity: 99.78%
Purity: 99.71%
Purity: 99%
Purity: 98.71%
Contact us for more batch information
Biological Description
Chemical Properties
Storage & Solubility Information
Description Venetoclax (ABT-199) is a Bcl-2 inhibitor (Ki<0.01 nM) with potent, selective, and orally active properties. Venetoclax has a 3-order-of-magnitude lower affinity for Bcl-xL and Bcl-W (Kis=48/245 nM). Venetoclax induces autophagy and apoptosis.
Targets&IC50 BCL-XL:48 nM (Ki, cell free), BCL2:<0.01 nM (Ki, cell free)
In vitro METHODS: Eleven human T-cell acute lymphoblastic leukemia cells T-ALL were treated with Venetoclax (0-12 μM) for 48 h. Cell viability was measured by Celltiter-Glo Luminescent Cell Viability Assay.
RESULTS: The IC50 values of Venetoclax against 11 T-ALL species ranged from 0.2-10 μM. [1]
METHODS: Human acute lymphoid leukemia cells RS4;11 were incubated with Venetoclax (0.01-5 μM) for 3.5 h. Caspase-3/7 activity was assessed using the Caspase-GLO kit.
RESULTS: Venetoclax induced the activation of caspases, which is one of the characteristics of apoptosis. [2]
METHODS: Human primary HCL leukemia cells were treated with Venetoclax (0.1-1 μM) for 24 h. Cell death was detected using Flow Cytometry method.
RESULTS: Venetoclax significantly increased cell death in HCL cells in a dose-dependent manner. [3]
In vivo METHODS: To test the antitumor activity in vivo, Venetoclax (100 mg/kg in 60% PG+30% PEG 400+10% ethanol) was orally administered once daily for twenty-one days to C.B-17 SCID-beige mice bearing human diffuse large B-cell lymphoma Toledo.
RESULTS: Venetoclax significantly inhibited the growth of Toledo tumor (TGImax=93%, TGD=220%). [2]
METHODS: To assay anti-tumor activity in vivo, Venetoclax (50 mg/kg in 10% ethanol+30% PEG 400+60% Phosal 50PG, administered orally once daily) and anti-PD-1 (10 mg/kg in PBS, administered intraperitoneally three times every four days) were administered to C57BL/6 mice harboring mouse colorectal carcinoma tumor MC38 for fourteen days.
RESULTS: Venetoclax enhances the antitumor efficacy of immune checkpoint inhibitors (ICIs) and increases PD-1+ T effector memory cells. Venetoclax does not impair human T-cell function in response to antigenic stimulation in vitro, nor does it antagonize anti-PD-1-induced T-cell activation. [4]
Kinase Assay The equilibrium binding experiments of fluorescent peptides to Bcl-xL protein were performed in an Analyst 96-well plate reader under the following conditions: each individual well in a 96-well assay plate contained 5 μl DMSO, 15 nM fluorescent peptide, and increasing concentrations (from 0 to 2.24 μM) of Bcl-xL protein in assay buffer in a final volume of 125 μl. The plate was mixed on a shaker for 1 min and incubated at room temperature for an additional 15 min. The polarization in millipolarization units (mP) was measured at room temperature with an excitation wavelength at 485 nm and an emission wavelength at 530 nm. For assay stability testing, a plate containing a binding experiment was measured at different times over a 24-h period. Between each reading, the plate was covered with parafilm to prevent any solution evaporation. To determine the effect of DMSO on the assay, binding experiments were performed under conditions similar to those described above except that the amount of DMSO was varied from 0 to 4 to 8%. All experimental data were analyzed using Prism 3.0 software and Kd values were generated by fitting the experimental data using a sigmoidal dose-response nonlinear regression model [1].
Cell Research RS4;11 cells were seeded at 50,000 per well in 96-well plates and treated with compounds diluted in half-log steps starting at 1 μM and ending at 0.00005 μM. All other leukemia and lymphoma cell lines were seeded at 15,000–20,000 cells per well in the appropriate medium and incubated with ABT-199 or navitoclax for 48 h. Effects on proliferation were determined using Cell TiterGlo reagent. EC50 values were determined by nonlinear regression analysis of the concentration-response data. Mouse FL5.12–BCL-2 and FL5.12–BCL-XL cells were propagated and assessed as described previously. Bak?/? Bax?/? double knockout mouse embryonic fibroblasts were seeded into 96-well microtiter plates at 5,000 cells per well in DMEM supplemented with 10% FBS. ABT-199 in the same culture medium was added in half-log dilutions starting at 5 μM. The cells were then incubated at 37 °C (5% CO2) for 48 h, and the effects on proliferation were determined using Cell TiterGlo reagent according to the manufacturer's instructions [1].
Animal Research Female C.B-17 SCID mice (DoHH2 and Granta-519 xenografts) and female C.B-17 SCID-beige mice (RS4;11 and Toledo xenografts) were inoculated with 1 × 10^6 (DoHH2) or 5 × 10^6 (Granta-519, Toledo and RS4;11) cells subcutaneously in the right flank. The inoculation volume (0.2 ml) comprised a 50:50 mixture of cells in growth media and Matrigel. Electronic calipers were used to measure the length and width of each tumor 2–3 times per week. Tumor volume was estimated by applying the following equation: volume = length × width2/2. When tumors reached approximately 220 mm3, mice were size matched (day 0) into treatment and control groups. All xenograft trials were conducted using ten mice per group, and all mice were ear tagged and monitored individually throughout the studies. ABT-199 was formulated for oral dosing in 60% phosal 50 propylene glycol (PG), 30% polyethylene glycol (PEG) 400 and 10% ethanol, and bendamustine and rituximab were formulated in accordance with the manufacturer's instructions. ABT-199 was delivered approximately 2 h before bendamustine or bendamustine plus rituximab. TGImax was calculated as the greatest treatment response using the following equation: TGImax = (1 ? mean tumor volume of the treated group/mean tumor volume of the vehicle control group) × 100. The TGD (%) was determined as the percentage increase of the median time period for the treatment group to reach an arbitrary tumor volume of 1,000 mm3 relative to the vehicle control group. A complete tumor regression response was the portion of the population with tumors ≤25 mm3 for at least three consecutive measurements [1].
Synonyms GDC-0199, ABT 199, ABT-199, ABT199
Molecular Weight 868.44
Formula C45H50ClN7O7S
CAS No. 1257044-40-8


Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Solubility Information

H2O: < 1 mg/mL (insoluble or slightly soluble)

Ethanol: < 1 mg/mL (insoluble or slightly soluble)

DMSO: 8.68 mg/mL (10 mM), Sonication is recommended.

TargetMolReferences and Literature

1. Peirs S, et al. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood. 2014 Dec 11;124(25):3738-47. 2. Souers AJ, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013 Feb;19(2):202-8. 3. Vereertbrugghen A, et al. In Vitro Sensitivity to Venetoclax and Microenvironment Protection in Hairy Cell Leukemia. Front Oncol. 2021 Jul 26;11:598319. 4. Kohlhapp FJ, et al. Venetoclax Increases Intratumoral Effector T Cells and Antitumor Efficacy in Combination with Immune Checkpoint Blockade. Cancer Discov. 2021 Jan;11(1):68-79. 5. Capoci I R G, Faria D R, Sakita K M, et al. Repurposing approach identifies new treatment options for invasive fungal disease[J]. Bioorganic chemistry. 2019 Mar;84:87-97.


1. Lima K, Pereira-Martins D A, de Miranda L B L, et al.The PIP4K2 inhibitor THZ-P1-2 exhibits antileukemia activity by disruption of mitochondrial homeostasis and autophagy.Blood cancer journal.2022, 12(11): 1-11. 2. Pan G, Zhong M, Yao J, et al.Orelabrutinib and venetoclax synergistically induce cell death in double-hit lymphoma by interfering with the crosstalk between the PI3K/AKT and p38/MAPK signaling.Journal of Cancer Research and Clinical Oncology.2022: 1-17. 3. Gao P, Zhang W, Fang X, et al.Simultaneous quantification of venetoclax and voriconazole in human plasma by UHPLC-MS/MS and its application in acute myeloid leukemia patients.Journal of Pharmaceutical and Biomedical Analysis.2023: 115279. 4. Li Z, Pan G, Zhong M, et al.High-Throughput Drug Screen for Potential Combinations With Venetoclax Guides the Treatment of Transformed Follicular Lymphoma.International Journal of Toxicology.2023: 10915818231178693. 5. e Silva, Catarina Sofia Mateus Reis, et al. Embelin potentiates venetoclax-induced apoptosis in acute myeloid leukemia cells. Toxicology in Vitro. (2021): 105207. 6. Takei H, Coelho‐Silva J L, Leal C T, et al. Suppression of multiple anti‐apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms. Cancer Science. 2022, 113(2): 597. 7. Suarez M, Blyth G T, Mina A A, et al. Inhibitory effects of Tomivosertib in acute myeloid leukemia. Oncotarget. 2021, 12(10): 955. 8. Tang J, Yao C, Liu Y, et al. Arsenic trioxide induces expression of BCL-2 expression via NF-κB and p38 MAPK signaling pathways in BEAS-2B cells during apoptosis. Ecotoxicology and Environmental Safety. 2021, 222: 112531. 9. Tan M, Ren F, Yang X. Anti-HBV therapeutic potential of small molecule 3, 5, 6, 7, 3′, 4′-Hexamethoxyflavone in vitro and in vivo. Virology. 2021 10. Lee J B, Khan D H, Hurren R, et al. Venetoclax enhances T cell-mediated anti-leukemic activity by increasing ROS production. Blood. 2021 Jul 22;138(3):234-245. doi: 10.1182/blood.2020009081.

Related compound libraries

This product is contained In the following compound libraries:
Anti-Cancer Drug Library Anti-Cancer Approved Drug Library Inhibitor Library EMA Approved Drug Library Highly Selective Inhibitor Library Drug Repurposing Compound Library Anti-Cancer Clinical Compound Library Anti-Cancer Active Compound Library ReFRAME Related Library Anti-Lung Cancer Compound Library

Related Products

Related compounds with same targets
BI-3812 (R)-(-)-Gossypol acetic acid Coronarin D Mcl1-IN-9 Myricanone 3',6-Disinapoylsucrose Kurarinone Sabutoclax

TargetMolDose Conversion

You can also refer to dose conversion for different animals. More

TargetMol In vivo Formulation Calculator (Clear solution)

Step One: Enter information below
Average weight of animals
Dosing volume per animal
Number of animals
Step Two: Enter the in vivo formulation
% Tween 80
% ddH2O
Calculate Reset


Molarity Calculator
Dilution Calculator
Reconstitution Calculation
Molecular Weight Calculator

Molarity Calculator allows you to calculate the

  • Mass of a compound required to prepare a solution of known volume and concentration
  • Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Concentration of a solution resulting from a known mass of compound in a specific volume
See Example

An example of a molarity calculation using the molarity calculator
What is the mass of compound required to make a 10 mM stock solution in 10 ml of water given that the molecular weight of the compound is 197.13 g/mol?
Enter 197.13 into the Molecular Weight (MW) box
Enter 10 into the Concentration box and select the correct unit (millimolar)
Enter 10 into the Volume box and select the correct unit (milliliter)
Press calculate
The answer of 19.713 mg appears in the Mass box


Calculator the dilution required to prepare a stock solution

Calculate the dilution required to prepare a stock solution
The dilution calculator is a useful tool which allows you to calculate how to dilute a stock solution of known concentration. Enter C1, C2 & V2 to calculate V1.

See Example

An example of a dilution calculation using the Tocris dilution calculator
What volume of a given 10 mM stock solution is required to make 20ml of a 50 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=50 μM, V2=20 ml and V1 is the unknown:
Enter 10 into the Concentration (start) box and select the correct unit (millimolar)
Enter 50 into the Concentration (final) box and select the correct unit (micromolar)
Enter 20 into the Volume (final) box and select the correct unit (milliliter)
Press calculate
The answer of 100 microliter (0.1 ml) appears in the Volume (start) box


Calculate the volume of solvent required to reconstitute your vial.

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial.
Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Enter the chemical formula of a compound to calculate its molar mass and elemental composition

Tip: Chemical formula is case sensitive: C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed n the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.


Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.


Venetoclax 1257044-40-8 Apoptosis Autophagy BCL bioavailable GDC0199 GDC-0199 orally inhibit Inhibitor Bcl-2 Family GDC 0199 ABT 199 ABT-199 ABT199 inhibitor